Skip to main content

Table 3 Postoperative short-term outcomes of each group (N = 353)

From: The effects of preoperative intestinal dysbacteriosis on postoperative recovery in colorectal cancer surgery: a prospective cohort study

Postoperative short-term outcomes

Preoperative intestinal dysbacteriosis

Sum

x2/H

P

Grade 1

(n = 268)

Grade 2

(n = 58)

Grade 3

(n = 27)

Early postoperative diarrhoea

38 (14.2%)

25 (43.1%)

13 (48.1%)

76 (21.5%)

32.704

 < 0.001†

Surgical complications

13 (4.9%)

6 (10.3%)

5 (18.5%)

24 (6.8%)

8.481

0.004†

 Incision infections

5 (1.9%)

1 (1.7%)

2 (7.4%)

8 (2.3%)

2.091

0.148†

 Abdominal/Pelvic infections

5 (1.9%)

2 (3.4%)

3 (11.1%)

10 (2.8%)

6.470

0.011†

 Anastomotic leakage

4 (1.5%)

3 (5.2%)

3 (11.1%)

10 (2.8%)

9.429

0.002†

Pulmonary infections

16 (6.0%)

7 (12.1%)

6 (22.2%)

29 (8.2%)

9.733

0.002†

Urinary tract infections

3 (1.1%)

1 (1.7%)

0 (0.0%)

4 (1.1%)

0.049

0.824†

Fever of unknown origin

2 (0.7%)

1 (1.7%)

0 (0.0%)

3 (0.8%)

0.002

0.963†

Total postoperative complications

34 (12.7%)

15 (25.9%)

11 (40.7%)

60 (17.0%)

17.481

 < 0.001†

Length of postoperative stay (days)

6.0 (3–32)

6.0 (3–32)

6.0 (3–31)

6.0 (3–16)

1.867

0.393

Length of antibiotics therapy (days)

2.0 (1–24)

2.0 (1–24)

3.0 (2–20)

2.0 (1–18)

9.791

0.007‡

Antibiotics regimen§, n(%)

 Cefoxitin or Cefmetazole

260 (97.0%)

54 (93.1%)

22 (81.5%)

336 (95.2%)

21.163

0.002

 Cefoperazone/sulbactam (Sulperazon)

3 (1.1%)

1 (1.7%)

3 (11.1%)

7 (2.0%)

  

 Piperacillin/tazobactam (Tazocin)

2 (0.7%)

2 (3.4%)

2 (7.4%)

6 (1.7%)

  

 Moxifloxacin (Avelox)

3 (1.1%)

1 (1.7%)

0 (0.0%)

4 (1.1%)

  
  1. The data are presented as n(%) for categorical variables or the median (range) for continuous variables
  2. †The P value was obtained by Chi-square test for trend
  3. ‡Pairwise multiple comparisons after Kruskal–Wallis test: grade 1 vs. grade 3, adjusted P < 0.05
  4. §Antibiotic regimen: cefoxitin or cefmetazole, 2.0 g Q8h, Sulperazon 3.0 g Q8h, tazoxin 4.5 g Q8h, avelox 0.4 g Qd